FDA requests technical updates for Biogen's high dose nusinersen application
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall St futures edge lower as caution builds ahead of Big Tech earnings
- Oil climbs over 3% to near six-week high as conflict threatens key oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Reddit shares drop as threat to cut off Google AI sparks standoff
- AT&T shares gain as Q2 earnings top forecasts, subscriber growth accelerates
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
- Myriad Genetics launches four-in-one prenatal genetic screen
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
September 23, 2025 4:30 PM EDTCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Companys supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be... More
